Oracle (NYSE:ORCL) was in focus on Thursday as investment firm Argus raised its earnings estimates and upgraded the IT tech giant after it reported fiscal third-quarter results. Shares were flat in ...

REDWOOD SHORES, Calif., Feb. 13, 2018 /PRNewswire/ -- Oracle Health Sciences today announced that the latest release of Oracle Argus, the company's safety and pharmacovigilance software, fully ...

Builds on Oracle's Endeavor to Provide an Integrated Pharmacovigilance Suite That Supports End-to-End Drug Safety Processes Across Clinical Development and Post-Market Surveillance As part of its ...

REDWOOD SHORES, CA--(Marketwired - Jun 24, 2013) - Oracle (NASDAQ: ORCL) News Facts To help health sciences organizations meet increasingly stringent regulatory requirements and ensure product safety ...

WASHINGTON, DC--(Marketwired - Jun 16, 2015) - DIA 2015 -- Oracle (NYSE: ORCL) -- Oracle Health Sciences today announced the availability of Oracle Argus Standard Edition 8.0, Oracle Argus Enterprise ...

Contract Research Organization aims to improve data management, accuracy, and safety with Oracle's AI-powered pharmacovigilance platform AUSTIN, Texas, July 8, 2025 /PRNewswire/ -- Contract Research ...

On Thursday, Oracle (NYSE:ORCL) received an upgrade from Argus, moving from a Hold to a Buy rating, accompanied by a new price target set at $145 per share. The upgrade follows Oracle's reported ...

Argus, a financial analysis firm, has upgraded its price target for Oracle Corporation (NYSE: NYSE:ORCL) from $159.00 to $176.00 while maintaining a Buy rating on the shares. The firm highlighted ...

Argus analyst Joseph Bonner raised the firm’s price target on Oracle (ORCL) to $200 from $176 and keeps a Buy rating on the shares after its Q2 results. The company is in the enviable position of ...

new and ever-changing pharmacovigilance and safety requirements. Efficient and effective management of these processes is vital from both a safety and business perspective," said Neil de Crescenzo, ...

NEW DELHI--(BUSINESS WIRE)--APCER Life Sciences, the preferred pharmacovigilance (PV) services provider for pharmaceutical and biotech companies seeking compliance and safety management solutions ...